Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
LYON, France, November 29, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will participate in a fireside chat and host investor 1x1 meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference,
View HTML
Toggle Summary EDAP Reports Third Quarter 2021 Results and Provides Operational Update
Year-to-date revenue of approximately EUR 30.1 million (USD 35.9 million) increased 14.4% year-over-year Q3 revenue of EUR 9.4 million (USD 11.1 million), flat with Q3 2020, reflecting lingering impact of COVID-19 on capital equipment sales Year-to-date US HIFU treatment volumes increased 58% over
View HTML
Toggle Summary EDAP TMS SA to Announce Third Quarter 2021 Financial Results on Wednesday, November 17, 2021
Company to host conference call and webcast on Thursday, November 18, at 8:30 am ET LYON, France, November 10, 20 21 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the third quarter ended September 30, 2021
View HTML
Toggle Summary EDAP Announces University of Washington Medicine to Launch Focal One® Robotic HIFU Program
Brings advanced focal ablation to prostate cancer patients in the Pacific Northwest LYON, France, September 28, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that University of Washington Medicine has acquired the company’s
View HTML
Toggle Summary EDAP Announces Presentation of Multiple Abstracts Favorably Comparing HIFU to Surgery at the American Urological Association 2021 Annual Meeting
Data demonstrate superiority of HIFU versus radical prostatectomy among prostate cancer patients LYON, France, September 14, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company’s Focal One and ExactVu technologies
View HTML
Toggle Summary EDAP to Participate at Upcoming Investor Conferences
LYON, France, September 7, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced that management will present at the following investor conferences during the month of September 2021: H.C.
View HTML
Toggle Summary EDAP Reports Second Quarter 2021 Results and Provides Operational Update
Total revenue for the first half 2021 of EUR 20.7 million (USD $24.8 million) increased 22.5% over the same period of the prior year Net income was EUR 0.4 million (USD 0.4 million), or EUR 0.01 per diluted share, for the first half of 2021 Cash balance of EUR 45 million (USD $53.3 million) as of
View HTML
Toggle Summary EDAP Announces Select Preliminary Unaudited Second Quarter 2021 Results
Total company second quarter 2021 revenue of approximately EUR 10.4 million (USD $12.4 million) increased 11.8% year-over-year; first half 2021 total company revenue of EUR 20.7 million (USD $24.8 million) increased 22.5% During the second quarter, U.S.
View HTML
Toggle Summary EDAP Issues Letter to Shareholders
Successful financing and hiring of MedTech industry veteran Ryan Rhodes to drive accelerated U.S. expansion efforts LYON, France, July 20, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today issued the following letter to shareholders: To
View HTML
Toggle Summary EDAP Announces Hiring of MedTech Industry Veteran Ryan Rhodes as CEO of Company’s U.S. Subsidiary
Appointment brings highly experienced medical technology and commercialization leader to drive EDAP’s US expansion focus. Career accomplishments include 14 years at Intuitive Surgical, where he played a leading role in global clinical expansion of robotic surgery in multiple specialties including
View HTML